X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for chronic weight management.
Lead Product(s): Mazdutide
Therapeutic Area: Nutrition and Weight Loss Product Name: IBI362
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Details:
IBI343 is an ADC composed of an anti-claudin18.2 antibody, and a cytotoxic drug exatecan. It is being investigated for advanced unresectable or metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): IBI343
Therapeutic Area: Oncology Product Name: IBI343
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2024
Details:
IBI112 (picankibart), an antibody, specifically binds to IL-23p19 inhibiting IL-23 receptor-mediated signaling pathway. It is being investigated in patients with moderate to severe plaque psoriasis.
Lead Product(s): Picankibart
Therapeutic Area: Dermatology Product Name: IBI112
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2024
Details:
IBI311 is an investigational, large molecule antibody works by inhibiting IGF-1R receptor, given intravenously for the treatment of thyroid eye disease.
Lead Product(s): IBI311
Therapeutic Area: Immunology Product Name: IBI311
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2024
Details:
IBI362 (mazdutide) is a glucagon-like peptide-1 receptor GLP-1R/GCGR dual agonist. It is being evaluated in phase 3 clinical trials for Type 2 Diabetes
Lead Product(s): Mazdutide
Therapeutic Area: Endocrinology Product Name: IBI362
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2024
Details:
IBI343 is an ADC composed of an anti-claudin18.2 antibody, and a cytotoxic drug exatecan. As a topoisomerase I inhibitor, exatecan effectively kills tumor cells by inhibiting DNA synthesis. It is being investigated for claudin-18.2-positive Gastric Cancer.
Lead Product(s): IBI343
Therapeutic Area: Oncology Product Name: IBI343
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2024
Details:
Fruzaqla (fruquintinib) is a selective oral VEGFR inhibitor it plays a pivotal role in blocking tumor angiogenesis. It is being investigated in combination with sintilimab (PD-1 inhibitor) for the treatment of advanced endometrial cancer.
Lead Product(s): Fruquintinib,Sintilimab
Therapeutic Area: Oncology Product Name: Fruzaqla
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Hutchmed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
IBI310 (anti-CTLA-4 monoclonal antibody) in combination with sintilimab (PD-1 inhibitor) is being evaluated for the treatment of MSI-H/dMMR Resectable Colon Cancer.
Lead Product(s): Ipilimumab,Sintilimab
Therapeutic Area: Oncology Product Name: IBI310
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
IBI302 (efdamrofusp alfa) is a recombinant human VEGFR-Fc-Human CR1 fusion protein injection. It is being evaluated for the treatment of patients with neovascular age-related macular degeneration.
Lead Product(s): Efdamrofusp alfa
Therapeutic Area: Ophthalmology Product Name: IBI302
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
AB-106 (taletrectinib) is a next-generation ROS1 tyrosine kinase inhibitor (TKI), which is being evaluated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Lead Product(s): Taletrectinib
Therapeutic Area: Oncology Product Name: AB-106
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: AnHeart Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
